These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 30430296

  • 1. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
    Pal R, Hameed S, Fatima Z.
    Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
    [Abstract] [Full Text] [Related]

  • 2. A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3.
    Dupont C, Chen Y, Xu Z, Roquet-Banères F, Blaise M, Witt AK, Dubar F, Biot C, Guérardel Y, Maurer FP, Chng SS, Kremer L.
    J Biol Chem; 2019 Nov 15; 294(46):17512-17523. PubMed ID: 31562241
    [Abstract] [Full Text] [Related]

  • 3. HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.
    Zheng H, Williams JT, Coulson GB, Haiderer ER, Abramovitch RB.
    Antimicrob Agents Chemother; 2018 Jul 15; 62(7):. PubMed ID: 29661875
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3.
    Hu T, Yang X, Liu F, Sun S, Xiong Z, Liang J, Yang X, Wang H, Yang X, Guddat LW, Yang H, Rao Z, Zhang B.
    Structure; 2022 Oct 06; 30(10):1395-1402.e4. PubMed ID: 35981536
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis.
    Belardinelli JM, Yazidi A, Yang L, Fabre L, Li W, Jacques B, Angala SK, Rouiller I, Zgurskaya HI, Sygusch J, Jackson M.
    ACS Infect Dis; 2016 Oct 14; 2(10):702-713. PubMed ID: 27737557
    [Abstract] [Full Text] [Related]

  • 8. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT, Haiderer ER, Coulson GB, Conner KN, Ellsworth E, Chen C, Alvarez-Cabrera N, Li W, Jackson M, Dick T, Abramovitch RB.
    Antimicrob Agents Chemother; 2019 Oct 14; 63(10):. PubMed ID: 31405862
    [Abstract] [Full Text] [Related]

  • 9. Allosteric coupling of substrate binding and proton translocation in MmpL3 transporter from Mycobacterium tuberculosis.
    Babii S, Li W, Yang L, Grzegorzewicz AE, Jackson M, Gumbart JC, Zgurskaya HI.
    mBio; 2024 Oct 16; 15(10):e0218324. PubMed ID: 39212407
    [Abstract] [Full Text] [Related]

  • 10. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.
    Li W, Sanchez-Hidalgo A, Jones V, de Moura VC, North EJ, Jackson M.
    Antimicrob Agents Chemother; 2017 Apr 16; 61(4):. PubMed ID: 28115355
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W, Upadhyay A, Fontes FL, North EJ, Wang Y, Crans DC, Grzegorzewicz AE, Jones V, Franzblau SG, Lee RE, Crick DC, Jackson M.
    Antimicrob Agents Chemother; 2014 Nov 16; 58(11):6413-23. PubMed ID: 25136022
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective.
    Chauhan M, Barot R, Yadav R, Joshi K, Mirza S, Chikhale R, Srivastava VK, Yadav MR, Murumkar PR.
    Chem Biol Drug Des; 2024 Sep 16; 104(3):e14612. PubMed ID: 39237482
    [Abstract] [Full Text] [Related]

  • 16. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014 Sep 16; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 17. Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.
    Fay A, Czudnochowski N, Rock JM, Johnson JR, Krogan NJ, Rosenberg O, Glickman MS.
    mBio; 2019 Jun 25; 10(3):. PubMed ID: 31239378
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis.
    Umare MD, Khedekar PB, Chikhale RV.
    ChemMedChem; 2021 Oct 15; 16(20):3136-3148. PubMed ID: 34288519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.